Hancock Whitney Corp Trims Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Hancock Whitney Corp lowered its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,928 shares of the biopharmaceutical company’s stock after selling 1,928 shares during the period. Hancock Whitney Corp’s holdings in Catalyst Pharmaceuticals were worth $774,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CPRX. Vanguard Group Inc. lifted its position in Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after purchasing an additional 860,244 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after buying an additional 263,099 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 130,918.8% during the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock worth $45,968,000 after acquiring an additional 2,965,310 shares during the last quarter. Janus Henderson Group PLC grew its position in Catalyst Pharmaceuticals by 139.5% in the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after acquiring an additional 1,587,794 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after acquiring an additional 287,300 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the subject of a number of research reports. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Finally, Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average price target of $31.14.

Catalyst Pharmaceuticals Stock Up 3.5 %

Shares of Catalyst Pharmaceuticals stock opened at $21.93 on Wednesday. The firm has a market cap of $2.62 billion, a PE ratio of 18.58, a price-to-earnings-growth ratio of 3.31 and a beta of 0.75. The company’s fifty day simple moving average is $21.14 and its two-hundred day simple moving average is $18.62. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.00 and a 12-month high of $24.27.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.